Their effects can arise at distinct levels: a variant may change the protein’s structure, reduce how much cystatin B is produced, decrease its stability, or alter its cellular localization. These mechanisms are not interchangeable. Separating them helps explain why two inherited CSTB changes can produce different effects on protease inhibition and provides a basis for assessing their biological significance.
Cystatin B must be present in the appropriate cellular location to regulate its target cysteine proteases effectively. A variant that lowers protein abundance, destabilizes the protein, or redirects it within the cell may weaken this control even if some inhibitory activity remains. The resulting imbalance can disturb intracellular protein turnover and clarify how a molecular change affects cell function.
Cathepsins are among the cysteine proteases regulated by cystatin B, so weakened inhibition may change proteolytic activity inside cells. Because intracellular protein turnover contributes to cellular maintenance, disruption of this balance offers a mechanistic connection between CSTB dysfunction and neuronal health. This relationship is particularly relevant when interpreting the biology of Unverricht–Lundborg disease.
Analysis links an inherited CSTB change with its possible molecular consequence, such as altered protein stability, abundance, localization, or protease inhibition. That interpretation can support genetic diagnosis by moving beyond the presence of a sequence change alone. It also helps distinguish variants that are more likely to disrupt cystatin B function from changes whose significance remains uncertain.
Pathogenicity assessment centers on whether the variant plausibly disrupts cystatin B biology. Relevant considerations include predicted effects on protein structure or production, stability, cellular localization, and regulation of cysteine proteases. Connecting these molecular consequences with conditions associated with CSTB dysfunction strengthens interpretation and helps place a variant within a biologically coherent disease model.
Comparing specific CSTB changes with observed disease features can reveal whether different molecular effects correspond to different phenotypes. Researchers can then relate variant classes to protease regulation, intracellular protein turnover, and neuronal health. This approach extends beyond diagnosis by using inherited variation to investigate how cystatin B dysfunction contributes to Unverricht–Lundborg disease and other associated conditions.